Analysts Set Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) PT at $3.33

Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) has earned an average recommendation of “Hold” from the five brokerages that are covering the stock, Marketbeat reports. Four equities research analysts have rated the stock with a hold rating and one has assigned a buy rating to the company. The average 12 month price target among brokers that have issued ratings on the stock in the last year is $3.33.

Several analysts have weighed in on the company. StockNews.com initiated coverage on Syros Pharmaceuticals in a report on Tuesday, December 31st. They issued a “sell” rating on the stock. HC Wainwright restated a “neutral” rating and issued a $1.00 target price (down previously from $6.00) on shares of Syros Pharmaceuticals in a research report on Wednesday, November 13th. JMP Securities restated a “market perform” rating on shares of Syros Pharmaceuticals in a research report on Wednesday, November 13th. TD Cowen restated a “hold” rating on shares of Syros Pharmaceuticals in a research report on Wednesday, November 13th. Finally, Brookline Capital Management restated a “hold” rating on shares of Syros Pharmaceuticals in a research report on Wednesday, November 13th.

Insider Buying and Selling at Syros Pharmaceuticals

In other Syros Pharmaceuticals news, Director Nancy A. Simonian sold 134,713 shares of the business’s stock in a transaction that occurred on Monday, November 25th. The stock was sold at an average price of $0.27, for a total value of $36,372.51. Following the completion of the sale, the director now owns 41,070 shares in the company, valued at approximately $11,088.90. The trade was a 76.64 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Corporate insiders own 12.26% of the company’s stock.

Institutional Trading of Syros Pharmaceuticals

Hedge funds and other institutional investors have recently bought and sold shares of the stock. GSA Capital Partners LLP purchased a new position in shares of Syros Pharmaceuticals during the third quarter valued at approximately $34,000. Acadian Asset Management LLC increased its stake in shares of Syros Pharmaceuticals by 101.5% during the second quarter. Acadian Asset Management LLC now owns 34,578 shares of the company’s stock valued at $178,000 after buying an additional 17,416 shares during the period. Certuity LLC purchased a new position in shares of Syros Pharmaceuticals during the second quarter valued at approximately $109,000. Finally, Exome Asset Management LLC increased its stake in shares of Syros Pharmaceuticals by 87.6% during the third quarter. Exome Asset Management LLC now owns 298,575 shares of the company’s stock valued at $642,000 after buying an additional 139,400 shares during the period. Institutional investors own 91.47% of the company’s stock.

Syros Pharmaceuticals Stock Performance

NASDAQ:SYRS opened at $0.26 on Thursday. The business’s 50-day moving average price is $0.79 and its two-hundred day moving average price is $2.49. Syros Pharmaceuticals has a twelve month low of $0.18 and a twelve month high of $7.98. The stock has a market cap of $7.02 million, a P/E ratio of -0.09 and a beta of 1.31. The company has a quick ratio of 2.25, a current ratio of 2.25 and a debt-to-equity ratio of 1.97.

Syros Pharmaceuticals (NASDAQ:SYRS) last released its quarterly earnings results on Thursday, October 31st. The company reported ($0.68) earnings per share for the quarter, beating the consensus estimate of ($0.76) by $0.08. During the same period in the previous year, the firm posted ($1.35) earnings per share. As a group, equities analysts predict that Syros Pharmaceuticals will post -2.94 EPS for the current fiscal year.

About Syros Pharmaceuticals

Syros Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors.